Obesity may be erythropoietin dose-saving in hemodialysis patients

Obesity may be erythropoietin dose-saving in hemodialysis patients

Background : In dialysis patients, the obesity-survival paradox still requires an explanation. Anemia and high doses of erythropoiesis-stimulating agents (ESAs) are associated with worse outcomes in the hemodialysis (HD) population. In the present study, we explored the relation between obesity and...

Full description

Bibliographic Details
Main Authors: Ghada M. El-Kannishy, Abir F. Megahed, Mona M. Tawfik, Ghada El-Said, Rabab T. Zakaria, Nahed A. Mohamed, Eman M. Taha, Alzhraa A. Ammar, Abeer M. Abd Eltawab, Nagy A. Sayed-Ahmed
Format: Article
Language:English
Published: The Korean Society of Nephrology 2018-06-01
Series:Kidney Research and Clinical Practice
Subjects:
Body mass index
Erythropoiesis-stimulating agents
Obesity
Renal Dialysis
Online Access:https://doi.org/10.23876/j.krcp.2018.37.2.148

Internet

https://doi.org/10.23876/j.krcp.2018.37.2.148

Similar Items